Skip to main content
Figure 1 | BMC Endocrine Disorders

Figure 1

From: A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy

Figure 1

Patient disposition. *Did not satisfy study inclusion and exclusion criteria. Abdominal pain secondary to partial small bowel obstruction (later classified as a serious AE, requiring hospitalization). Values did not meet the exclusion criteria; however, the investigator chose to withdraw the patient for safety reasons.

Back to article page